Abivax Shares Rise +4.49% After a 19% Decline Over Three Months
The stock of French biotech company Abivax saw a significant increase this Wednesday, climbing 4.49% to €97.80 during the session. This rebound comes after several weeks of decline, with the stock having lost nearly 19% over the last three months. In a Parisian market also on the rise, with the CAC 40 up 2.12% during the session, the stock is attempting to regain lost ground.
Current Market Position of Abivax
Abivax's stock is currently trading below its 20-day and 50-day moving averages, which are at €99.40 and €101.15 respectively, indicating ongoing short-term bearish pressure. The RSI, at 42, remains in a zone of weakness but does not yet indicate extreme overselling, leaving room for the rebound observed this Wednesday. The technical support identified at €88.80 has not been threatened in recent sessions, while the stock will need to break through the resistance at €112.40 to invalidate the downward trend of recent weeks. The monthly volatility remains particularly high, at 56.37, characteristic of a biotechnological stock in clinical development phase. The negative beta of -0.94 confirms that the stock does not behave in correlation with benchmark indices, indicating that today's dynamics are more related to factors specific to the stock than a simple sector-wide momentum effect. It is also noted that peers in the healthcare sector are also posting gains this Wednesday: Sanofi is up 0.42% and UCB has gained 3.17%.
Long-term Perspective Despite Recent Declines
While the quarterly decline is significant, the perspective radically changes on a twelve-month scale. Abivax's stock shows an annual performance of 1,601%, reflecting major advancements made by the company in the development of its flagship drug candidate, obefazimod, targeting chronic inflammatory diseases. The stock is significantly above its 200-day moving average, set at €78.89, confirming the strength of the long-term upward trend despite recent corrections. The next key event is marked on the financial calendar: the publication of the first quarter 2026 results is scheduled for June 1st. Investors will monitor data related to cash flow and progress in the clinical program. The semi-annual results are expected on September 14th. These milestones could be crucial catalysts for the stock's direction in the coming months, as the global geopolitical context, marked by tensions in the Middle East, maintains a high level of stress on the markets, with the VIX having reached 31.05 points at its last close.
